Drugs / APL-4098
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06372717 | Jun 2024 → Mar 2027 expected | acute myeloid leukemia, myelodysplastic syndrome with excess blasts | Apollo Therapeutics Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APL-4098 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06372717 ↗ |
| Route | Oral | “APL-4098 is administered orally” NCT06372717 ↗ |